Dr. Sweis on Immunotherapy in Genitourinary Cancer

Video

In Partnership With:

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the use of immunotherapy in genitourinary cancer.

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the use of immunotherapy in genitourinary cancer.

In both bladder and kidney cancers, immunotherapy has become standard of care in practice, states Sweis. Currently-approved therapies include frontline nivolumab (Opdivo) and ipilimumab (Yervoy). Most patients who are diagnosed with these malignancies will be treated with an immunotherapy agent unless they have contraindications, explains Sweis.

Immunotherapy has adopted a greater role in the treatment paradigm over the past several years, which makes monitoring for immune-related adverse events very important. It is important for both patients and physicians to be aware of the potential side effects that can occur with immunotherapy use, notes Sweis. These side effects are more often than not different than what a patient might anticipate based on their understanding of historical treatments like chemotherapy. This understanding also extends to the various targeted therapies in kidney cancer, adds Sweis.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute